Literature DB >> 27311362

Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis.

Maria I Carlo1, Darren R Feldman2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27311362      PMCID： PMC6615055          DOI： 10.1016/j.eururo.2016.05.040

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  3 in total

1.  Pseudoprogression and Immune-Related Response in Solid Tumors.

Authors:  Victoria L Chiou; Mauricio Burotto
Journal:  J Clin Oncol       Date:  2015-08-10       Impact factor: 44.544

2.  Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy.

Authors:  Mizuki Nishino; Lynette M Sholl; F Stephen Hodi; Hiroto Hatabu; Nikhil H Ramaiya
Journal:  N Engl J Med       Date:  2015-07-16       Impact factor: 91.245

3.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245
  3 in total
  17 in total

1.  Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma.

Authors:  Hiroki Ishihara; Hironori Fukuda; Hidekazu Tachibana; Kazuhiko Yoshida; Hirohito Kobayashi; Toshio Takagi; Junpei Iizuka; Hideki Ishida; Yoji Nagashima; Tsunenori Kondo; Kazunari Tanabe
Journal:  Clin Exp Nephrol       Date:  2021-02-27       Impact factor: 2.801

2.  Nivolumab and ipilimumab immunotherapy for hemodialysis patients with advanced renal cell carcinoma.

Authors:  Y Kobayashi; H Arai; M Honda
Journal:  Curr Oncol       Date:  2020-08-01       Impact factor: 3.677

3.  Successful Response to Nivolumab Plus Ipilimumab Therapy in a Hemodialysis Patient With Metastatic Renal Cell Carcinoma.

Authors:  Hiroshi Masuda; Kosuke Mikami; Kotaro Otsuka; Kyokusin Hou; Takahito Suyama; Kazuhiro Araki; Satoko Kojima; Yukio Naya
Journal:  Cancer Diagn Progn       Date:  2021-07-03

Review 4.  Use of Immune Checkpoint Inhibitors in End Stage Kidney Disease Patients, Single Center Experience and Review of the Literature.

Authors:  Jamie S Hirsch; Rimda Wanchoo; Jia H Ng; Yuriy Khanin; Kenar D Jhaveri
Journal:  Kidney360       Date:  2020-03-18

5.  Rapidly progressing programmed cell death 1 inhibitor-related pneumonitis in a hemodialytic patient with metastatic renal cell carcinoma.

Authors:  Yoshiaki Matsumura; Yusuke Iemura; Shinji Fukui; Yoshihiro Tatsumi; Yoriaki Kagebayashi; Shoji Samma
Journal:  IJU Case Rep       Date:  2019-04-10

Review 6.  Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review.

Authors:  Nizar M Tannir; Sumanta K Pal; Michael B Atkins
Journal:  Oncologist       Date:  2018-02-27

Review 7.  Renal toxicity of targeted therapies for renal cell carcinoma in patients with normal and impaired kidney function.

Authors:  Łukasz Mielczarek; Anna Brodziak; Paweł Sobczuk; Maciej Kawecki; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Cancer Chemother Pharmacol       Date:  2021-03-25       Impact factor: 3.333

8.  Three Cases of Nivolumab Plus Ipilimumab Therapy in Haemodialysis Patients With Metastatic Renal Cell Carcinoma.

Authors:  Yuki Kobari; Kazuhiko Yoshida; Junpei Iizuka; Tsunenori Kondo; Hideki Ishida; Kazunari Tanabe; Toshio Takagi
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

9.  Safe and effective use of nivolumab plus ipilimumab in a patient with metastatic clear-cell renal cell carcinoma with sarcomatoid dedifferentiation and end stage renal disease on hemodialysis.

Authors:  Leah K Shaw; Andrew J Wiele; Kanishka Sircar; Christopher G Wood; Pavlos Msaouel
Journal:  Cancer Treat Res Commun       Date:  2021-03-10

10.  Efficacy of Nivolumab in a Patient with Metastatic Renal Cell Carcinoma and End-Stage Renal Disease on Dialysis: Case Report and Literature Review.

Authors:  Jawaher Ansari; Muhammad Ali; Ashraf Farrag; Arwa M Ali; Abdulaziz Alhamad
Journal:  Case Reports Immunol       Date:  2018-06-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.